📊 HRMY Key Takeaways
Is Harmony Biosciences Holdings, Inc. (HRMY) a Good Investment?
Harmony Biosciences demonstrates exceptional financial health with a fortress balance sheet, 77.2% gross margins, and 40.1% free cash flow margins in a capital-light business model. However, flat net income growth (+0% YoY) despite 21.5% revenue growth warrants investigation into margin compression and operational efficiency, presenting both opportunity and execution risk.
Harmony shows strong revenue growth, industry-leading margins, and exceptional free cash flow backed by a cash-rich, low-leverage balance sheet. Profitability and returns on capital are solid, positioning the company to invest in growth and withstand shocks. Sustaining margin discipline and mitigating product/regulatory concentration risks are key to maintaining earnings momentum.
Why Buy Harmony Biosciences Holdings, Inc. Stock? HRMY Key Strengths
- Exceptional gross margin of 77.2% with 24.0% operating margin indicates strong pricing power and operational efficiency in pharmaceuticals
- Fortress balance sheet with $752.5M cash, low 0.19x debt-to-equity ratio, and 3.60x current ratio provides significant strategic flexibility
- Outstanding free cash flow generation of $347.9M (40.1% FCF margin) from capital-light operations with minimal $310K capex requirement
- Strong return metrics with 18.2% ROE and 12.5% ROA demonstrate excellent capital deployment and shareholder value creation
- High gross and operating margins indicating pricing power
- Robust free cash flow (40% FCF margin) with minimal capex needs
- Strong balance sheet with ample cash, low debt, and high interest coverage
HRMY Stock Risks: Harmony Biosciences Holdings, Inc. Investment Risks
- Net income growth flat at 0% YoY despite 21.5% revenue growth suggests margin pressure or operating expense deleverage requiring investigation
- Pharmaceutical sector inherent risks including regulatory changes, patent cliffs, drug competition, and clinical trial uncertainties
- Elevated insider activity with 10 Form 4 filings in 90 days requires monitoring for potential concerns or shifts in management sentiment
- Product concentration and patent/regulatory exposure could pressure revenue durability
- Flat net income YoY despite strong sales suggests cost pressure or one-offs
- Potential reimbursement and competitive pressures could compress margins
Key Metrics to Watch
- Net income growth reacceleration and driver analysis of YoY margin compression
- Gross margin preservation as revenue scales and gross profit sustainability
- Operating expense ratio trends and ability to leverage fixed cost base
- Free cash flow sustainability and working capital efficiency quarter-over-quarter
- Revenue growth YoY
- Operating margin
Harmony Biosciences Holdings, Inc. (HRMY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 40.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.60x current ratio provides a solid financial cushion.
HRMY Profit Margin, ROE & Profitability Analysis
HRMY vs Healthcare Sector: How Harmony Biosciences Holdings, Inc. Compares
How Harmony Biosciences Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Harmony Biosciences Holdings, Inc. Stock Overvalued? HRMY Valuation Analysis 2026
Based on fundamental analysis, Harmony Biosciences Holdings, Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Harmony Biosciences Holdings, Inc. Balance Sheet: HRMY Debt, Cash & Liquidity
HRMY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Harmony Biosciences Holdings, Inc.'s revenue has grown significantly by 184% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.13 reflects profitable operations.
HRMY Revenue Growth, EPS Growth & YoY Performance
HRMY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $186.0M | $46.1M | $0.79 |
| Q2 2025 | $172.8M | $11.6M | $0.20 |
| Q1 2025 | $154.6M | $38.3M | $0.67 |
| Q3 2024 | $160.3M | $38.5M | $0.63 |
| Q2 2024 | $134.2M | $11.6M | $0.20 |
| Q1 2024 | $119.1M | $29.5M | $0.48 |
| Q3 2023 | $117.2M | $38.5M | $0.63 |
| Q2 2023 | $107.0M | $23.5M | $0.39 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Harmony Biosciences Holdings, Inc. Dividends, Buybacks & Capital Allocation
HRMY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Harmony Biosciences Holdings, Inc. (CIK: 0001802665)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HRMY
What is the AI rating for HRMY?
Harmony Biosciences Holdings, Inc. (HRMY) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are HRMY's key strengths?
Claude: Exceptional gross margin of 77.2% with 24.0% operating margin indicates strong pricing power and operational efficiency in pharmaceuticals. Fortress balance sheet with $752.5M cash, low 0.19x debt-to-equity ratio, and 3.60x current ratio provides significant strategic flexibility. ChatGPT: High gross and operating margins indicating pricing power. Robust free cash flow (40% FCF margin) with minimal capex needs.
What are the risks of investing in HRMY?
Claude: Net income growth flat at 0% YoY despite 21.5% revenue growth suggests margin pressure or operating expense deleverage requiring investigation. Pharmaceutical sector inherent risks including regulatory changes, patent cliffs, drug competition, and clinical trial uncertainties. ChatGPT: Product concentration and patent/regulatory exposure could pressure revenue durability. Flat net income YoY despite strong sales suggests cost pressure or one-offs.
What is HRMY's revenue and growth?
Harmony Biosciences Holdings, Inc. reported revenue of $868.5M.
Does HRMY pay dividends?
Harmony Biosciences Holdings, Inc. does not currently pay dividends.
Where can I find HRMY SEC filings?
Official SEC filings for Harmony Biosciences Holdings, Inc. (CIK: 0001802665) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HRMY's EPS?
Harmony Biosciences Holdings, Inc. has a diluted EPS of $2.71.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HRMY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Harmony Biosciences Holdings, Inc. has a BUY rating with 79% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is HRMY stock overvalued or undervalued?
Valuation metrics for HRMY: ROE of 18.2% (sector avg: 15%), net margin of 18.3% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy HRMY stock in 2026?
Our dual AI analysis gives Harmony Biosciences Holdings, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is HRMY's free cash flow?
Harmony Biosciences Holdings, Inc.'s operating cash flow is $348.2M, with capital expenditures of $310.0K. FCF margin is 40.1%.
How does HRMY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 18.3% (avg: 12%), ROE 18.2% (avg: 15%), current ratio 3.60 (avg: 2).